NovaBridge Biosciences (NBP) — Financial statements
Income statement, balance sheet, and cash flow for NovaBridge Biosciences — annual and quarterly history with growth and margin analysis.
| Metric (CNY Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 4↑141.9% | -11↓112.2% | 88 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 27↓41.3% | 46 | |
| Gross Profit | 0.00 | 0.00↓100.0% | 4↑101.8% | -249↓698.2% | 42 | |
| Operating Expenses | ||||||
| R&D Expenses | 63↓60.4% | 159↑38.9% | 114↓26.5% | 156↓18.3% | 190 | |
| General & Administrative Expenses | 31↓85.5% | 216↑238.7% | 64↓92.2% | 816↓9.4% | 900 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 31↓85.5% | 216↑238.7% | 64↓68.0% | 200↓77.8% | 900 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 337↑136591547.4% | -0.00↓100.0% | 1,023 | |
| Operating Expenses | 94↓74.9% | 375↓27.2% | 516↑45.1% | 355↓83.2% | 2,113 | |
| Total Costs & Expenses | 94↓74.9% | 375↓27.2% | 516↑45.1% | 355↓83.5% | 2,159 | |
| Operating Results | ||||||
| Operating Income | -94↑74.9% | -375↑26.6% | -511↓39.6% | -366↑82.3% | -2,071 | |
| Depreciation & Amortization | 0.86↓55.1% | 2↓43.5% | 3↑138.2% | 1↓89.7% | 14 | |
| EBITDA | -93↑75.0% | -373↓8.5% | -344↓572.0% | -51↑97.5% | -2,058 | |
| EBIT | -94↑74.9% | -375↓8.0% | -348↓560.3% | -53↑97.5% | -2,071 | |
| Interest & Other Income | ||||||
| Net Interest Income | 8↓86.1% | 55↑659.1% | 7↑45.3% | 5↓76.8% | 21 | |
| Interest Income | 8↓86.1% | 55↑648.5% | 7↑47.4% | 5↓76.8% | 21 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.10 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -164 | 0.00 | 0.00 | |
| Other Income / Expenses | 6↓53.0% | 13↑101.3% | -955↓57.2% | -607↓132.8% | -261 | |
| Income Before Tax | -88↑75.6% | -363↑75.3% | -1,466↓50.6% | -973↑58.3% | -2,332 | |
| Income Tax Expense | 0.00 | 0.00↑100.0% | -1,259↓180720.7% | 0.70↑240.9% | -0.49 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -88↑75.6% | -363↓75.4% | -207↑91.8% | -2,507↓7.5% | -2,332 | |
| Net Income from Discontinued Operations | 0.00↓100.0% | 200 | 0.00 | 0.00 | 0.00 | |
| Net Income | -46↑71.5% | -162↑88.9% | -1,466↑41.5% | -2,507↓7.5% | -2,332 | |
| Bottom-Line Net Income | -46↑87.2% | -363↑75.3% | -1,466↑41.5% | -2,507↓7.5% | -2,332 | |
| EPS (Basic) | -1.10↑75.3% | -4.46↑74.7% | -17.62↑42.0% | -30.38↑1.0% | -30.70 | |
| EPS (Diluted) | -1.10↑75.3% | -4.46↑74.7% | -17.62↑42.0% | -30.38↑1.0% | -30.68 | |
| Weighted Average Shares | 42↓48.7% | 81↓2.4% | 83↑0.8% | 83↑8.7% | 76 | |
| Weighted Average Diluted Shares | 42↓48.7% | 81↓2.5% | 83↑0.9% | 83↑8.6% | 76 | |
* All figures in Millions of CNY, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.